Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
Open Access
- 1 January 2017
- journal article
- research article
- Published by Hindawi Limited in Anemia
- Vol. 2017, 1-9
- https://doi.org/10.1155/2017/9642027
Abstract
Objective. To evaluate safety and efficacy of intravenous ferric carboxymaltose (FCM) versus standard medical care (SMC) for iron-deficiency anemia (IDA) in postpartum women and women with heavy menstrual bleeding. Study Design. This open-label, multicenter study randomized women with IDA (hemoglobin ≤ 11.0 g/dL) to single doses of FCM (15 mg/kg [maximum 1000 mg]) or SMC (this treatment was determined by the investigator and there may have been no treatment). Safety data (primary outcome) were collected for 30 days. Results. Of 2045 subjects enrolled (FCM: ; SMC: ), 996 received FCM and 1022 received SMC. At least 1 serious adverse event (AE) was reported by 0.6% and 2.2% of subjects in the FCM and SMC groups, respectively; none were considered treatment related. The difference in serious AEs was primarily due to higher rates of uterine leiomyoma, uterine hemorrhage, and menorrhagia in SMC subjects with heavy menstrual bleeding. Common AEs were generally predictable, with higher rates of infusion site reactions in FCM subjects and gastrointestinal AEs in SMC subjects. Mean hemoglobin increases were greater in the FCM group than the SMC group. Conclusion. FCM was well tolerated and effectively increased mean hemoglobin levels in postpartum women or women with heavy menstrual bleeding and IDA. This trial is registered with ClinicalTrials.gov, NCT00548860.
Keywords
Funding Information
- Luitpold Pharmaceuticals
This publication has 21 references indexed in Scilit:
- How we diagnose and treat iron deficiency anemiaAmerican Journal of Hematology, 2015
- Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- A systematic analysis of global anemia burden from 1990 to 2010Blood, 2014
- Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in womenJournal of Bone and Mineral Research, 2013
- Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled TrialsAnemia, 2012
- FGF-23: More than a regulator of renal phosphate handling?Journal of Bone and Mineral Research, 2010
- Iron Deficiency and Erythropoiesis: New Diagnostic ApproachesClinical Chemistry, 2003
- Safety in iron managementAmerican Journal of Kidney Diseases, 2003
- High prevalence of postpartum anemia among low-income women in the United StatesAmerican Journal of Obstetrics and Gynecology, 2001
- The safety of intravenous iron dextran in hemodialysis patientsAmerican Journal of Kidney Diseases, 1996